Literature DB >> 11895871

The relation of reproductive factors to mortality from breast cancer.

Janet R Daling1, Kathleen E Malone, David R Doody, Benjamin O Anderson, Peggy L Porter.   

Abstract

Young women with breast cancer have been reported to have an increased risk of dying from their disease if they have given birth in <2 years before diagnosis. The prognostic factors associated with the tumors of these women have not been thoroughly studied. We examined the tumors of the women who had a recent birth and compared the tumor characteristics with those of women who were nulliparous or had given birth > or =5 years before diagnosis. A follow-up study was conducted of 1174 women <45 years old whose invasive ductal breast cancer was diagnosed from January 1983 to December 1992 in three counties of western Washington. These women had participated previously in a population-based, case-control study. Mean follow-up time was 105.4 months. Histological slides were collected for 79.1% of the tumors and reviewed by the study pathologist. Using immunoperoxidase assays, tumor tissue was tested for prognostic markers for 70.4% of the tumors from the women. Cox proportional hazards models were used to estimate the relative risk of dying from breast cancer associated with reproductive events. Logistic regression was used to obtain estimates of the association between various reproductive factors and tumor characteristics. At the end of follow-up, 48.2% of the women (n = 83) whose last birth occurred in < 2 years of diagnosis had died, compared with 23.3% of nulliparous women (n = 189) and 24.4% of the women (n = 661) whose last birth was > or =5 years before diagnosis. The tumors of the women with a recent birth (<2 years before diagnosis) were more likely to be progesterone receptor negative, odds ratio (OR) = 2.2, 95% confidence interval (CI) = 1.2-3.9, to be p53 positive, OR = 2.6, 95% CI = 1.5-4.7, to be of high histological grade, OR = 5.9, 95% CI = 1.7-20.1, to have high mitotic count, OR = 2.2, 95% CI = 1.4-4.4, to be node positive, OR = 2.1, 95% CI = 1.3-3.5, to have a high S phase fraction, OR = 2.3, 95% CI = 1.1-4.8, and to have a high American Joint Committee on Cancer stage (III+), OR = 2.8, 95% CI 1.3-5.8, compared with the tumors of nulliparous women. After adjusting for tumor characteristics and treatment, the risk of mortality associated with a birth in < 2 years of diagnosis of breast cancer remained an independent predictor of mortality, hazard radio (HR) = 2.7, 95% CI = 1.6-4.3. Our study provides evidence that reproductive factors influence the biological behavior of breast cancer in young women and prognosis. Clinicians need to be aware that women who have delivered a child in < 2 years before diagnosis are at increased risk of having tumors with especially adverse prognostic profiles and have a poorer survival rate than women who are nulliparous or whose last birth was some years in the past.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895871

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  41 in total

Review 1.  Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.

Authors:  Sarah C Baumgarten; Jonna Frasor
Journal:  Mol Endocrinol       Date:  2012-02-02

2.  Multiple births and breast cancer prognosis: a population based study.

Authors:  Lukman Thalib; Suhail A R Doi; Per Hall
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

3.  Carcinogenesis and metastasis now in the third dimension--what's in it for pathologists?

Authors:  Carlos Sonnenschein; Ana M Soto
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

4.  Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis.

Authors:  Shauntae M McDaniel; Kristen K Rumer; Sandra L Biroc; Richard P Metz; Meenakshi Singh; Weston Porter; Pepper Schedin
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 5.  Mammary gland involution as an immunotherapeutic target for postpartum breast cancer.

Authors:  Jaime Fornetti; Holly A Martinson; Courtney B Betts; Traci R Lyons; Sonali Jindal; Qiuchen Guo; Lisa M Coussens; Virginia F Borges; Pepper Schedin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-06-22       Impact factor: 2.673

6.  Effect of prediagnostic alcohol consumption on survival after breast cancer in young women.

Authors:  Kerryn W Reding; Janet R Daling; David R Doody; Cecilia A O'Brien; Peggy L Porter; Kathleen E Malone
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-29       Impact factor: 4.254

7.  Polycyclic aromatic hydrocarbon-DNA adducts and survival among women with breast cancer.

Authors:  Sharon K Sagiv; Mia M Gaudet; Sybil M Eng; Page E Abrahamson; Sumitra Shantakumar; Susan L Teitelbaum; Paula Bell; Joyce A Thomas; Alfred I Neugut; Regina M Santella; Marilie D Gammon
Journal:  Environ Res       Date:  2009-01-31       Impact factor: 6.498

8.  Histological type and grade of breast cancer tumors by parity, age at birth, and time since birth: a register-based study in Norway.

Authors:  Grethe Albrektsen; Ivar Heuch; Steinar Ø Thoresen
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

9.  The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival.

Authors:  Anna H Wu; Scarlett Lin Gomez; Cheryl Vigen; Marilyn L Kwan; Theresa H M Keegan; Yani Lu; Salma Shariff-Marco; Kristine R Monroe; Allison W Kurian; Iona Cheng; Bette J Caan; Valerie S Lee; Janise M Roh; Jane Sullivan-Halley; Brian E Henderson; Leslie Bernstein; Esther M John; Richard Sposto
Journal:  Cancer Causes Control       Date:  2013-07-18       Impact factor: 2.506

Review 10.  Pregnancy and breast cancer: when they collide.

Authors:  Traci R Lyons; Pepper J Schedin; Virginia F Borges
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-04-21       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.